Drug Profile
Research programme: coronavirus infection therapies - Pfizer
Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antivirals; Indoles; Pyrrolidinones; Small molecules
- Mechanism of Action Coronavirus-3C-like-proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
- Discontinued Severe acute respiratory syndrome
Most Recent Events
- 28 Dec 2022 Preclinical development in COVID-2019 infections is ongoing in USA
- 16 Jul 2016 No recent reports of development identified for research development in Severe acute respiratory syndrome in USA
- 20 Aug 2009 Early research in Severe acute respiratory syndrome in USA (unspecified route)